Scholar Rock has started dosing patients with facioscapulohumeral muscular dystrophy in the Phase 2 FORGE trial of apitegromab while securing both Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for the new indication. FORGE will enroll approximately 60 adults with genetically confirmed FSHD and randomize them equally to intravenous apitegromab 10 mg/kg or placebo every four weeks for 52 weeks. The primary endpoint is change in total lean muscle volume measured by MRI, with additional imaging, functional, pharmacokinetic and safety measures intended to determine whether selective myostatin inhibition can produce meaningful muscle improvement in a disease with no approved therapy.
The program extends a molecule already substantially advanced in spinal muscular atrophy into a biologically different neuromuscular disease. Scholar Rock emphasizes that apitegromab became the first muscle-targeted candidate to demonstrate statistically significant and clinically meaningful improvement in motor function in a pivotal Phase 3 SMA study when added to SMN-targeted therapy. FSHD now tests whether the same fundamental strategy of releasing the body’s natural brake on muscle growth can produce benefit when muscle loss originates from a different genetic mechanism.
What is facioscapulohumeral muscular dystrophy?
FSHD is a hereditary muscular dystrophy characterized by progressive weakness and atrophy that frequently begins in the muscles of the face, shoulder blades and upper arms before affecting the trunk and lower extremities. The course can differ markedly between patients, but progressive weakness can impair mobility, independence and daily function while contributing to chronic pain and fatigue.
Scholar Rock estimates diagnosed prevalence at roughly one in 20,000 people, corresponding to approximately 40,000 individuals across the United States and European Union, although underdiagnosis may mean the actual population is larger. There are currently no therapies approved specifically to treat FSHD, leaving rehabilitation, supportive care and management of complications as major components of treatment.
How does apitegromab work?
Myostatin is a naturally occurring protein that limits skeletal-muscle growth. Apitegromab is a fully human monoclonal antibody designed to selectively bind the pro- and latent forms of myostatin and prevent its activation within skeletal muscle. Scholar Rock’s approach is intended to increase muscle-building capacity without broadly blocking related growth factors throughout the body.
The strategy is different from correcting the genetic defect responsible for FSHD. Apitegromab does not attempt to repair the underlying DUX4-associated disease mechanism; it instead seeks to improve the amount or quality of remaining muscle despite the continuing genetic disease process. This could make the treatment complementary to future disease-modifying therapies if muscle growth translates into improved strength and function.
Why is lean muscle volume the primary endpoint in FORGE?
The trial’s primary endpoint is percentage change from baseline in total lean muscle volume at week 52 as measured by magnetic resonance imaging. MRI can quantify muscle tissue and fat replacement across multiple muscle groups, giving investigators an objective structural measure of whether myostatin inhibition is producing anabolic activity. Secondary assessments include lean muscle volume at week 24, muscle fat fraction and safety, while exploratory endpoints will examine functional performance.
This endpoint strategy is important because increasing muscle volume does not automatically mean patients become stronger or function better. A successful Phase 2 program will therefore need to show a coherent relationship between MRI changes and functional measurements rather than relying entirely on larger muscles visible on imaging. FORGE is designed partly to establish that relationship before Scholar Rock determines whether and how to proceed into pivotal testing.
What evidence supports trying myostatin inhibition in FSHD?
Scholar Rock says its translational work used the FLExDUX4 FSHD mouse model and showed that a murine version of apitegromab increased muscle mass, strength and endurance. The company also cites broader evidence suggesting anabolic stimulation can produce muscle hypertrophy and functional benefit in FSHD.
Animal evidence alone cannot predict clinical success, particularly in a slowly progressive and heterogeneous muscular dystrophy. The value of the preclinical program is that it provides a mechanistic reason to undertake FORGE, while the randomized human trial will determine whether the observed biological effect is large enough to matter in actual patients.
Why do the new FDA designations matter?
Fast Track designation can provide more frequent FDA interaction and opportunities for expedited development when criteria are met, while Orphan Drug designation recognizes development for a rare condition and can provide regulatory and commercial incentives. Neither designation establishes efficacy, predicts approval or lowers the requirement for persuasive clinical evidence.
Their practical importance is that Scholar Rock can discuss trial design, endpoint selection and future development strategy with the FDA while the Phase 2 study progresses. That could become particularly useful if MRI and functional outcomes produce different signals and the company needs to determine which endpoint would be most appropriate for a pivotal FSHD program.
Is this the same apitegromab already under FDA review in spinal muscular atrophy?
Yes, but the indications and evidence packages are separate. Apitegromab has been developed most extensively for spinal muscular atrophy, where Scholar Rock has pursued approval based on clinical evidence showing improved motor outcomes when muscle-targeted treatment is added to therapies acting on survival motor neuron biology. The FSHD program represents a new use of the same myostatin-inhibition mechanism.
That creates an interesting platform question. If apitegromab eventually succeeds in both SMA and FSHD, the medicine could validate myostatin inhibition as a broader therapeutic strategy across diseases where muscle weakness persists even when the upstream genetic or neurological mechanism differs.
What should the FSHD community watch next?
The first meaningful milestone will be whether FORGE enrollment progresses as planned and whether 52-week MRI measurements show a clear separation from placebo. Functional measures will likely attract even greater attention because patients ultimately need improvements in strength, movement and independence rather than an imaging result alone.
FORGE is still a Phase 2 trial of around 60 people, so even a positive outcome would normally be followed by substantially larger confirmatory development before FSHD approval could be considered. Scholar Rock has nevertheless moved beyond a preclinical expansion idea: patients are now receiving the drug, the FDA has formally recognized the rare-disease development program, and the next dataset will show whether a mechanism validated in SMA can travel into an entirely different muscular dystrophy.
